This week’s killer Coronavirus stock is Co-Diagnostics (CODX) which is a medical diagnostics company. Percentage wise, gains rocketed to 500% this week with the stock price going from $3 dollar range all the way up to $15 and above.
Share of the company from a 1 year period would have landed you a nice 1,415.00% gain right to your brokerage account.
The Driving Force Behind Corona-virus stock Co-Diagnostics
You may be asking what’s driving this stock upwards? Well there’s a few things that is driving the stock upwards. First and foremost, the company has gained regulatory clearance for the Logix Smart Coronavirus COVID-19 test.
As a result of this clearance, the diagnostic test will become immediately available for export from the United States as a CE-marked in-vitro diagnostic. This can be rapidly used to diagnose patients of suspected of having COVID-19 in countries that accept CE marking (meets Europe’s standards).
COVID-19 Corona-virus is hard to Diagnose
Diagnosing COVID-19’s illness has proved to be tough for a variety of reasons. This creates a medical need for easy to use molecular diagnostics. CO-Diagnostics hopes that their Logix Smart Coronavirus COVID-19 test can fill this gap.
This product can soon turn out to be the huge boom for the company and with a number of cases spiking in recent days this spells a wonderful investment to investors who bought in cheap.
2 Stocks We Recommend You Buy
- Aptose Biosciences (APTO) $8.20 – Highly under valued stock, has potential to be bought out and showing similar signs like ArQule (ARQL) with it’s BTK Inhibitor.
- Sunesis Pharmaceuticals (SNSS) $0.87 – Highly valued candidate “Vecabrutinib” has the ability to be combined to make combos with other therapies for better results like with a combo of Vecabrutinib and a Kinase Inhibitor to target Car-T, also has potential for acquisition.
